United Therapeutics (NASDAQ:UTHR) Sees Unusually-High Trading Volume – What’s Next?

United Therapeutics Corporation (NASDAQ:UTHR) shares saw an uptick in trading volume on Friday . 512,556 shares were traded during trading, an increase of 5% from the previous session’s volume of 490,146 shares.The stock last traded at $528.82 and had previously closed at $532.94.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Quarterly earnings exceeded expectations. United Therapeutics reported second-quarter EPS of $7.27, above the roughly $6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a favorable fundamental backdrop. United Therapeutics Q2 Earnings Beat Estimates
• Positive Sentiment: Pipeline milestones are offsetting near-term product concerns. Investors are focusing on progress for ralinepag, including its Phase 3 milestone and regulatory applications. The program could provide a new growth driver and reduce reliance on Tyvaso amid competitive pressures. EPS Strength and Ralinepag’s Phase 3 Milestone
• Positive Sentiment: Analyst sentiment remains favorable. H.C. Wainwright reiterated a Buy rating with a $660 price target. RBC maintained an Outperform rating and set a $677 target, despite reducing its previous target from $704. These targets indicate continued confidence in United Therapeutics’ longer-term prospects. Buy Rating Reiterated on United Therapeutics
• Neutral Sentiment: Revenue fell short of estimates. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down 1.9% year over year. The revenue miss highlights near-term pressure even as earnings and pipeline updates were encouraging. United Therapeutics Q2 Earnings Results
• Negative Sentiment: Senior executives sold sizable positions. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, while EVP Paul Mahon sold 8,300 shares for about $4.3 million. The transactions may reflect personal or scheduled sales, but the reductions in insider ownership could weigh on investor sentiment. United Therapeutics Insider Selling

Wall Street Analyst Weigh In

Several research firms recently issued reports on UTHR. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, July 31st. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Price Performance

The stock’s 50 day moving average price is $539.43 and its two-hundred day moving average price is $534.22. The firm has a market capitalization of $23.11 billion, a price-to-earnings ratio of 19.28, a PEG ratio of 1.83 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter last year, the firm posted $6.41 EPS. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.32 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Jan Malcolm sold 325 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $550.59, for a total value of $178,941.75. Following the sale, the director owned 450 shares of the company’s stock, valued at $247,765.50. This trade represents a 41.94% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,356,182.60. This trade represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 482,833 shares of company stock worth $265,555,592 in the last 90 days. 8.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Torren Management LLC acquired a new stake in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC raised its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.